Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20073784 | 0.81 | HTT (0.43) | HTTALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL25509748 | 0.79 | HTT (0.41) | HTTALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL16794437 | 0.78 | MEN1 (0.40) | HTTALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL26100639 | 0.77 | HTT (0.36) | HTTALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL22421138 | 0.77 | HTT (0.41) | HTTALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL14917639 | 0.77 | LMNA (0.47) | HTTALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL173687 | 0.76 | HTT (0.38) | HTTALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL16622729 | 0.76 | HTT (0.38) | HTTALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL31497522 | 0.76 | HTT (0.38) | HTTALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL611566 | 0.74 | HTT (0.38) | HTTALDH1A1MEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240270747-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2024-08-15 | — | — | US | disclosed |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230167110-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | SCHRÖDINGER, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20230167110-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | SCHRÖDINGER, INC. | 2023-06-01 | — | — | US | disclosed |
| EP-4050012-A1 | PYRIDONE BORONATES FOR THE PREPARATION OF INHIBITORS OF BTK ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2022-08-31 | — | — | EP | disclosed |
| EP-4019508-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2022-06-29 | — | — | EP | disclosed |
| EP-3521288-B1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | HOFFMANN LA ROCHE (CH) | 2021-09-08 | — | — | EP | disclosed |
| US-20210079002-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2021-03-18 | — | — | US | disclosed |
| US-RE48239-E1 | Heteroaryl pyridone and aza-pyridone compounds | GENETECH, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20200062769-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2020-02-27 | — | — | US | disclosed |
| US-8669251-B2 | 8-fluorophthalazin-1(2H)-one compounds | GENENTECH, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-8669251-B2 | 8-fluorophthalazin-1(2H)-one compounds | GENENTECH, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-8669251-B2 | 8-fluorophthalazin-1(2H)-one compounds | GENENTECH, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| WO-2013067274-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | GENENTECH, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013067264-A1 | 8-FLUOROPHTHALAZIN-1 (2H) - ONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | GENENTECH, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013067264-A1 | 8-FLUOROPHTHALAZIN-1 (2H) - ONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | GENENTECH, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130116235-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116246-A1 | 8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116246-A1 | 8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116246-A1 | 8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116246-A1 | 8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS | BTK, LCK, SYK | HTT 4310/4885ALDH1A1 4769/4885MEN1 3319/4885 |
| US-20240270747-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | HTT 3865/4885ALDH1A1 4561/4885MEN1 2841/4885 |
| US-20230167110-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | HTT 1969/4885ALDH1A1 3735/4885MEN1 3963/4885 |
| US-20200062769-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | HTT 3865/4885ALDH1A1 4561/4885MEN1 2841/4885 |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | HTT 3865/4885ALDH1A1 4561/4885MEN1 2841/4885 |
| US-20130116235-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | BTK, PDXK, TYK2 | HTT 4627/4885ALDH1A1 4251/4885MEN1 2334/4885 |
| US-20210079002-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | HTT 3865/4885ALDH1A1 4561/4885MEN1 2841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.